This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Assessment of Interactions Between Methamphetamine and Aripiprazole - 1

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2005 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
Information provided by:
National Institute on Drug Abuse (NIDA) Identifier:
First received: August 5, 2004
Last updated: January 10, 2017
Last verified: July 2005
The purpose of this study is to assess the interactions between intravenous methamphetamine and aripiprazole.

Condition Intervention Phase
Amphetamine-Related Disorders Drug: Aripiprazole Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Assessment of Interactions Between IV Methamphetamine and Aripiprazole

Resource links provided by NLM:

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Adverse effect measures
  • pharmacokinetic assessment

Estimated Enrollment: 17
Study Start Date: June 2004
Estimated Study Completion Date: March 2005
Detailed Description:
This is a double-blind, placebo-controlled human laboratory clinical pharmacology study to assess potential interactions between intravenous d-methamphetamine infusion and treatment with oral aripiprazole.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Must meet DSM-4 criteria for methamphetamine abuse or dependence and are non-treatment seeking.
  • Ability to verbalize understanding of the consent form, able to provide written informed consent, and verbalize willingness to complete study procedures.

Exclusion Criteria:

  • Please contact the site for more information.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00089440

United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, New York
New York University, School of Medicine
New York, New York, United States, 10016
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Principal Investigator: Thomas Newton, M.D. University of California, Los Angeles
  More Information Identifier: NCT00089440     History of Changes
Other Study ID Numbers: NIDA-MDS-0002-1
Study First Received: August 5, 2004
Last Updated: January 10, 2017

Additional relevant MeSH terms:
Amphetamine-Related Disorders
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Psychotropic Drugs
Central Nervous System Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors processed this record on September 21, 2017